BRNS - Company ID 0001828185
Barinthus Biotherapeutics plc. trades as BRNS. In its fiscal 2025 annual report the company posted revenue of $0.00, down 100.0% from the prior year and net income of -$66.43M. This page tracks Barinthus Biotherapeutics plc. through 247 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
With latest filings
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Net profit margin compressed from -367.3% to -408.0% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| Major company event | 8-K | 2026-05-21 |
| New insider ownership | 3 | 2026-05-01 |
| Quarterly report | 10-Q | 2026-04-30 |
| Major company event | 8-K | 2026-04-30 |
| DEFM14A | - | 2026-04-30 |
| Major company event | 8-K | 2026-04-22 |
| SCHEDULE 13D | - | 2026-04-13 |
| Major company event | 8-K | 2026-03-31 |
The largest companies sharing Barinthus Biotherapeutics plc.'s SEC industry classification (pharmaceutical preparations).
Barinthus Biotherapeutics plc. reported revenue of $0.00 for fiscal year 2025, a decrease of 100.0% year over year.
In its latest fiscal year Barinthus Biotherapeutics plc. reported a net loss of $66.43M.